Johnson & Johnson 2nd-quarter sales down in top 2 markets but up sharply in emerging markets
By APTuesday, July 20, 2010
J&J sales down in US, Europe but up elsewhere
Sales of most categories of Johnson & Johnson consumer health products were down in the first quarter, particularly the over-the-counter drugs/nutritionals category. That’s because of repeated recalls of pain relievers and some other nonprescription medicines and the shutdown of a factory that made them.
| SECOND-QUARTER SALES TRENDS | U.S. | Change | Foreign | Change | Global | Change | ||||||
| Over-the-Counter/Nutritionals: | $492 | M | Down | 28% | $649 | M | Up | 3% | $1.14 | B | Down | 13% |
| Wound Care/Other: | $165 | M | Down | 12% | $123 | M | Down | 17% | $288 | M | Down | 14% |
| Oral Care: | $148 | M | Down | 15% | $224 | M | Up | 6% | $372 | M | Down | 4% |
| Women’s Health: | $137 | M | Down | 10% | $329 | M | Flat | $466 | M | Down | 3% | |
| Skin Care: | $422 | M | Up | 3% | $421 | M | Flat | $843 | M | Up | 1% | |
| Baby Care: | $99 | M | Down | 5% | $438 | M | Up | 8% | $537 | M | Up | 6% |
| Total Consumer: | $1.46 | B | Down | 14% | $2.18 | B | Up | 2% | $3.65 | B | Down | 5% |
Source: Johnson & Johnson
YOUR VIEW POINT
